SAN CARLOS, Calif., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of ...

Acurx (ACXP) Pharmaceuticals announced updates on Phase 3 Readiness for Ibezapolstat in C. difficile Infection based on recent FDA and EMA communications. Acurx’s Executive Chairman, Bob DeLuccia, ...

Researchers have identified new roles for a protein long known to protect against severe flu infection -- among them, raising the minimum number of viral particles needed to cause sickness.

Biomolecular phase separation-mediated immunity was recently uncovered as an important strategy of plants and animals for their survival in the challenging environment. Effectors are powerful weapons ...

Delve into bronchiectasis, a field long focused on managing symptoms that now has its first targeted treatment with ...

Lyon, France – July 28, 2023 – Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses, today announced that The Lancet ...

Researchers have identified new roles for a protein long known to protect against severe flu infection—among them, raising the minimum number of viral particles needed to cause sickness. The protein ...

Curevo is developing amezosvatein, a next-generation shingles vaccine currently in phase 2 testing. In head-to-head studies, the vaccine reportedly matched the immune response of the GSK Shingrix ...

MUMBAI, India & HYDERABAD, India--(BUSINESS WIRE)--PopVax, an Indian full-stack biotechnology company developing novel mRNA vaccines and therapeutics using machine learning-enabled computational ...

Memo Therapeutics is pressing ahead with its kidney transplant infection drug, advancing it to Phase III trials, despite falling short of its primary endpoint in a Phase II trial. The SAFE KIDNEY II ...